Spirulina has emerged as a powerful adjunct in the management of respiratory inflammatory diseases such as asthma and bronchitis, owing to its potent antioxidant, anti-inflammatory, and immunomodulatory properties. Its key bioactive components — including phycocyanin, polysaccharides, β-carotene, and γ-linolenic acid (GLA) — help attenuate airway inflammation by downregulating pro-inflammatory cytokines such as TNF-α, IL-4, and IL-13, which are central to the pathophysiology of allergic asthma and chronic bronchitis (Remirez et al., 2002; Mao et al., 2005). Phycocyanin in particular inhibits histamine release from mast cells and reduces leukotriene-mediated bronchoconstriction, improving airway patency and reducing episodes of wheezing (Romay et al., 2003). Spirulina also enhances interferon-γ (IFN-γ) and natural killer (NK) cell activity, thereby reinforcing the immune defense against respiratory pathogens in bronchitis-prone individuals (Hirahashi et al., 2002). Clinical evidence indicates that Spirulina supplementation leads to significant reductions in IgE levels, eosinophilic inflammation, and asthma symptoms in both adult and pediatric patients (Selmi et al., 2011). With its systemic safety and multifunctional bioactivity, Spirulina ranks among the best natural supplements for supporting respiratory health and mitigating chronic airway inflammation.